Endpoint Validation Study (0524A-015)

A Randomized, Double-Blind, Placebo-Controlled Endpoint Selection and Questionnaire Validation Study to Assess the Niacin Induced Flushing Caused by NIASPAN (TM)

To determine the most effective daily dose of MK0524A when compared with placebo after the 8-week treatment period for Niacin Induce Flushing (NIF).

Inclusion Criteria:

• Patients must be male or female between 18 to 70 years
• Qualified women must be sterile (through surgery) and/or post-menopausal, and/or agree to use birth control

Exclusion Criteria:

• You are a woman who is having hot flashes, receiving Hormone Replacement Therapy (HRT), and/or other therapies for hot flashes
• You are currently using Niacin/or Niacin containing products with a daily dose over 50 mg/day
• You are sensitive to niacin
• You have a history gout
• You drink more than 2 glasses of alcohol per day and you are not willing to stop
• You don't have access to a telephone